290 related articles for article (PubMed ID: 30909223)
1. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
[TBL] [Abstract][Full Text] [Related]
2. Tau aggregation is a therapeutic target for Alzheimer's disease.
Takashima A
Curr Alzheimer Res; 2010 Dec; 7(8):665-9. PubMed ID: 20678070
[TBL] [Abstract][Full Text] [Related]
3. [Significance of tau in the development of Alzheimer's disease].
Takashima A
Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
[TBL] [Abstract][Full Text] [Related]
4. Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.
Chen Q; Du Y; Zhang K; Liang Z; Li J; Yu H; Ren R; Feng J; Jin Z; Li F; Sun J; Zhou M; He Q; Sun X; Zhang H; Tian M; Ling D
ACS Nano; 2018 Feb; 12(2):1321-1338. PubMed ID: 29364648
[TBL] [Abstract][Full Text] [Related]
5. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.
Spires-Jones TL; Friedman T; Pitstick R; Polydoro M; Roe A; Carlson GA; Hyman BT
Neurosci Lett; 2014 Mar; 562():63-8. PubMed ID: 24462887
[TBL] [Abstract][Full Text] [Related]
6. "Drug-Carrier" Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.
Han G; Bai K; Yang X; Sun C; Ji Y; Zhou J; Zhang H; Ding Y
Adv Sci (Weinh); 2022 May; 9(14):e2106072. PubMed ID: 35307993
[TBL] [Abstract][Full Text] [Related]
7. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
8. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease.
Cornejo A; Jiménez JM; Caballero L; Melo F; Maccioni RB
J Alzheimers Dis; 2011; 27(1):143-53. PubMed ID: 21785188
[TBL] [Abstract][Full Text] [Related]
9. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
[TBL] [Abstract][Full Text] [Related]
10. [Present and future of the tau dementia therapy].
Takashima A
Rinsho Shinkeigaku; 2013; 53(11):1040-2. PubMed ID: 24291873
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
Sun W; Lee S; Huang X; Liu S; Inayathullah M; Kim KM; Tang H; Ashford JW; Rajadas J
Sci Rep; 2016 Oct; 6():34784. PubMed ID: 27708431
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease.
Maeda S; Sahara N; Saito Y; Murayama S; Ikai A; Takashima A
Neurosci Res; 2006 Mar; 54(3):197-201. PubMed ID: 16406150
[TBL] [Abstract][Full Text] [Related]
14. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
[TBL] [Abstract][Full Text] [Related]
15. Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.
Obulesu M; Venu R; Somashekhar R
Neurochem Res; 2011 Aug; 36(8):1329-35. PubMed ID: 21509508
[TBL] [Abstract][Full Text] [Related]
16. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
17. Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation.
Sonawane SK; Uversky VN; Chinnathambi S
Cell Commun Signal; 2021 Feb; 19(1):16. PubMed ID: 33579328
[TBL] [Abstract][Full Text] [Related]
18. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.
Hochgräfe K; Sydow A; Matenia D; Cadinu D; Könen S; Petrova O; Pickhardt M; Goll P; Morellini F; Mandelkow E; Mandelkow EM
Acta Neuropathol Commun; 2015 May; 3():25. PubMed ID: 25958115
[TBL] [Abstract][Full Text] [Related]
19. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
Zhang ZX; Zhao RP; Wang DS; Li YB
Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
[TBL] [Abstract][Full Text] [Related]
20. The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons.
Chua SW; Cornejo A; van Eersel J; Stevens CH; Vaca I; Cueto M; Kassiou M; Gladbach A; Macmillan A; Lewis L; Whan R; Ittner LM
ACS Chem Neurosci; 2017 Apr; 8(4):743-751. PubMed ID: 28067492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
